This placebo-controlled, randomized, double-blind study was designed to determine the effect on silent ischemia of one antianginal drug, sustained-release diltiazem. In addition to this primary goal, the trial was expected to provide useful data to define the features of symptomatic and asymptomatic ST segment depression in a population of patients with stable coronary artery disease, to provide an insight into the pathophysiology of silent ischemia both during daily life and during exercise, and to yield clues to the mechanism of its suppression by diltiazem. For this purpose, the relation between heart rate and episodes of ST segment depression was closely monitored, and the effects of the drug on ST depression during ambulatory ECG monitoring and during exercise testing were compared.
Methods

Patient Selection
Sixty patients who meet all of the following criteria were included in the study: 1) documented coronary artery disease, 2) stable symptoms in Canadian Cardiovascular Society classes 1-3 without rest, nocturnal, progressive, or unstable angina and without a recent (.3 months) myocardial infarction, 3) a positive treadmill exercise test according to the Bruce protocol, with 1.0 mm or more horizontal or downsloping ST depression measured 0.08 msec after the J point, with or without angina, and 4) the presence of 10 minutes or more of silent ST depression 1 mm or more in amplitude or four or more asymptomatic episodes, each lasting for at least 1 minute during 24 hours of a continuous 72-hour screening ambulatory ECG. The criteria used for the diagnosis of coronary artery disease were 1) presence of at least one coronary artery stenosis greater than 50% lumen diameter reduction, 2) a well-documented previous myocardial infarction, or 3) a positive thallium exercise test manifested by a significant exercise-induced reversible defect. Holter ECG eligibility could be determined at the clinical center, but confirmation within 72 hours by the central ECG laboratory was required or the patient would be dropped from the study.
Exclusion criteria included 1) cardiac surgery within the previous 3 months, 2) stroke within the previous 6 months; 3) congestive heart failure, 4) known valvular heart disease, 5) the presence of atrial arrhythmias, sinus bradycardia of 50 beats/min or less, ventricular preexcitation, pacemaker, conduction abnormalities, left ventricular hypertrophy, or ST depression on the resting 12-lead ECG; 6) hypertension of 160 mm Hg or more systolic or 90 mm Hg or more diastolic and hypotension of 100 mm Hg or less systolic. The study was approved by the respective Hospital Ethics Committees, and all patients gave written, informed consent for participation in the study.
One hundred ninety-six patients were screened in the five clinical centers, and 118 were excluded before study entry; the most-common exclusion factor was failure to exhibit ST depression during the 72 hours of ambulatory ECG monitoring. Eighteen patients began the trial and could not be included in the analysis because they had no ambulatory ECG recording or treadmill exercise test during the doubleblind phase of the study: 10 leads. Patients were instructed to maintain their normal daily activities and to record their activities, symptoms, and medications in a diary.
All tapes were analyzed by the Ambulatory ECG Analysis Central Laboratory at the Montreal Heart Institute using the Cardiodata MK4 Playback System (Cardiodata, Northborough, Mass.). Tapes were independently read by a technician and one physician; both were unaware of patient identity and treatment assignment. An ischemic episode was defined by the standard criteria of transient ST depression of 1 mm or more lasting for at least 1 minute. In the present study, the duration of the ischemic episode was calculated from the onset of ST depression to return to baseline. An isoelectric segment lasting for at least 1 minute was required between episodes. All episodes of ST depression that were identified on the trend analysis were validated by visual inspection of the ECG tracings, recorded at a paper speed of 25 mm/sec before, at the beginning, peak, and end of the ST depression. Artifacts, apparent positional changes, and upsloping ST depression of 1 mm or less at 0.06 msec after the J point were disregarded. Borderline ST depression was also not counted unless the configuration was clearly ischemic and similar to other episodes of ST depression of 1 mm or more in the same patient The total number of ischemic episodes and the cumulative duration were used as study end points. Heart rate was calculated 5 minutes before and at the peak of ST segment shift and as the mean per hour for the 72-hour recordings.
Intraobserver variability was studied by rereading in a blind fashion 50 tapes selected at random among the 941 study tapes. The coefficient of correlation between the two readings from the same patient was 0.93 for the number of episodes and 0.91 for the total duration. The interobserver reliability was studied by having 50 randomly selected tapes interpreted by an independent laboratory that also used the Cardiodata MK4 Playback System. The coefficients of correlation between the two independent readings of the same patient were 0.87 for number of episodes and 0.90 for total duration of ischemic episodes. Exercise Tolerance Testing A maximal symptom-limited treadmill exercise test was performed at the baseline screening visit to identify eligible patients. The test was repeated at the end of each double-blind treatment phase, just before the end of the 72-hour continuous ECG recording period. All tests were performed in the morning, at the same time of day for each patient, and 2-3 hours after ingestion of a dose of the study drug. The Bruce protocol was used, and the following were recorded: blood pressure and heart rate at each stage and at each end point, reasons for stopping the test, time of onset of angina and of 1-mm ST depression, peak ST depression, maximum ST segment shift, and total exercise duration.' The exercise tests were interpreted by the principal investigator at each clinical center. Statistical Analysis Data were analyzed using the SAS (Statistical Analysis System, Cary, N.C.), version 5.18 with Virtual Memory System. Because of the nonnormal distribution of angina frequency, nitroglycerin consumption, and frequency and duration of ischemia on Holter monitoring, statistical tests were performed by use of a parametric procedure (ANOVA) with the ranked data (ImanConnover method28). Results for these data are presented as medians and ranges to comply with the nonnormal distribution and as means+SD as justified by the rank transformation of the data. Data on clinical characteristics and on the exercise test parameters followed a normal distribution and were analyzed by x2 and t statistics. They are presented as mean±SD. Comparisons between the two treatments during the double-blind phase of the study were performed following the Grizzle model for a two-period Latin square design for repeated measures. Any possible residual (carry-over) effect and period effect can also be determined by this model. A center-by-treatment interaction was ruled out using a two-way analysis of variance for repeated measures. Interobserver and intraobserver variability in ambulatory ECG interpretation and the relation between episodes of ST segment depression and changes in heart rate were studied with regression correlation coefficents. The significance level for inferential procedures was fixed at 5%.
Results
Study Population
All 60 patients in this study had documented coronary artery disease and reversible ischemia, expressed as transient ST Among the 60 patients studied, 10 became completely free of silent ischemic episodes with diltiazem, 31 improved by 50% or more, and nine improved by less than 50%. The number of episodes remained unchanged in two patients and increased in the remaining eight. The cumulative duration of ST depression exhibited a similar pattern.
The median number of episodes was 4.5 (range, 0-19) with placebo and 1.5 (range, 0-13) with diltiazem administration. Means were, respectively, 5.59±3.78 and 2.83+2.45, for a 50% reduction (p=O.OOOl) (Figure 1 ). The cumulative duration of ST depression was similarly reduced by 44%, from a median of 78.5 (range, 0-60) minutes to 24.5 (range, 0-411) minutes, with a mean of 119±107 to 67±92 minutes (p=0.001). The beneficial effect of diltiazem was maintained throughout the circadian cycle: the percent reduction in episodes was 54% from midnight to 6:00 AM, 48% from 6:00 AM to noon, 57% from noon to 6:00 PM, and 47% from 6:00 PM to midnight.
Average heart rate during the 72-hour placebo monitoring period was 74.3+14.3 beats/min compared with 68.5 ± 12.9 during the diltiazem treatment period (p<0.001). This reduction in heart rate was maintained around the clock, being only slightly less during the night compared with that during the day. The distribution of episodes of ST depression during both placebo and diltiazem treatment phases did not parallel the absolute heart rate distribution but was related to heart rate variation (Figure 2) . Thus, the heart rate acceleration observed between 6:00 and 9:00 AM was accompanied by an increasing incidence of ischemic episodes and the slowing between 8:00 PM and midnight by a decreased incidence. With the more constant heart rate observed at other times, episodes of ST segment depression were stable, being slightly less with slower heart rates.
Episodes of ST depression occurred at a slower heart rate with diltiazem than with placebo treatment, 66.1 +-9.8 beats/min versus 74.3-+9.8 (p= 0.001). Heart rate was, however, similar at the point of maximal ST depression, 114.1±f 17 Of the 78 patients evaluated for adverse effects, including the 18 omitted from the efficacy analysis, one or more symptoms were reported during the diltiazem phase in 25 (32%) and during the placebo phase in 18 (23%). Most of these symptoms were minor and not necessarily drug related. The most frequently encountered in the diltiazem and placebo phases, respectively, were headache (13 and eight), fatigue (five and two), edema (four and three), nausea (four and three), and dizziness (three and two). During diltiazem therapy, intermittent periods of atrioventricular dissociation were observed in two patients and of Mobitz type I second-degree atrioventricular block in two others; these were asymptomatic.
In six patients, serious adverse events required termination of the study. During the placebo periods, two patients experienced a myocardial infarction and another died suddenly. During diltiazem therapy, one patient developed urticaria, one developed heart failure, and another reported worsening angina.
Discussion
In this study, diltiazem used as single therapy reduced by one half the frequency of silent ischemic episodes occurring during daily life. Exercise test parameters were also significantly improved, although the magnitude of the improvement was less than that observed during ambulatory ECG monitoring. Diltiazem also reduced angina attacks by one half, but this difference was not significant because angina was uncommon in these patients. Thus, the benefit of diltiazem on silent episodes could not be readily inferred from the symptomatic response of patients.
Characteristics of Silent Ischemia
As shown in previous studies, most episodes of ST depression occurring during daily life are not associated with symptoms.3'6"4-17 The 95% proportion of silent episodes in our study was somewhat higher than the 75-85% rates usually reported.3'6'14-17 The total number of episodes, as well as the frequency of angina, during placebo treatment was also in the low range of previously reported values.6"1"4-16 The duration of episodes of ST depression was, however, near the median.26'17.'9 Our study population was selected to include a relatively homogeneous group of patients with stable coronary artery disease, effort angina, a positive exercise test, and silent ST depression on ambulatory ECG monitoring to minimize the possibility of detecting a differential effect of diltiazem because of different population subsets. Most of the patients were nonsmoking men with multivessel disease.
The methodology and diagnostic criteria were similar to that used in most previous studies. Defining the beginning and the end of an episode as the point of change from baseline, rather than at 0.5 or 1 mm, affects the duration of an episode but not the number of episodes. A 72-hour monitoring period was selected because of the variability in the frequency and duration of episodes of ST depression.6-8 Previous studies have estimated sample size requirements for various degrees of therapeutic efficacy at different levels of power.7 Longer monitoring periods with shorter intervals between them reduce sample size requirements. The large number of patients enrolled in our study and the long monitoring periods thus allow high statistical power to detect a beneficial effect.
Effect of Diltiazem
Previous studies indicate that long-acting nitrates, 14,17,22 3-blockers,16"18-21 and calcium antagonists21-23 may be useful to control silent ischemia.
Sustained-release diltiazem was selected for this study because of its favorable effect on heart rate and because of our previous finding of a sustained protective effect against spontaneous angina and of increased exercise performance 12 hours after dose administration. 29 The improvement in exercise test parameters in this study, with a reduction in heart rate and rate-pressure product at peak exercise, is similar to what we reported previously.29
The 50% reduction in episodes of ST depression is consistent with the results of the retrospective study by Frishman and Teicher21 and with studies comparing diltiazem with propranolol20 and with atenolol.2 Different results were noted in a preliminary report of a recent double-blind randomized trial using propranolol, diltiazem, and nifedipine.27 In that report, the number of episodes of ST depression was reduced by 10% with diltiazem, a difference that was not significant, and by 52% with propranolol. Also, nifedipine had no detectable effect, and only diltiazem significantly prolonged total exercise duration. Why diltiazem was less effective in preventing silent ischemic episodes, compared with our study, is uncertain.
Mechanism ofAction
The pathophysiological mechanisms involved in asymptomatic ST segment depression occurring during daily life, and the respective roles of increased myocardial oxygen demand or of decreased supply are as yet incompletely defined. The study does not allow an accurate characterization of myocardial oxygen demand because blood pressure and the inotropic state of the left ventricle were not continmay be relevant to the understanding of the mechanisms of silent ischemia.
First, ST segment depression occurred at a slower heart rate with diltiazem than with placebo treatment, and no circadian variation in the efficacy of diltiazem was found; the drug reduced both heart rate and ischemic episodes in a parallel and sustained fashion throughout the day. Second, the ischemic-type ST depression on ambulatory ECG monitoring was much more responsive to the drug than were any of the parameters measured during exercise testing. Third, the frequency of ST depression appeared to be modulated more by changes in heart rate than by the absolute heart rate. An accelerating heart rate was associated with a higher frequency of ischemic episodes, and the reverse was also true. When heart rate was relatively constant, episodes were less frequent. These observations suggest that one of the mechanisms involved in the pathogenesis of silent ischemia is a rapid rate of change in myocardial oxygen demand and that diltiazem has a beneficial effect by attenuating rapid increases in demand. Similar observations were recently made with ST depression occurring during treadmill exercise testing; with lower intensity exercise protocols, the onset of ST segment depression was delayed and occurred at a lower heart rate, documenting the importance of work load. 31, 32 The relation between heart rate reduction and efficacy is, however, not clear. In the study by Khurmi et a120 using propranolol and in the study by Bonetti et a130 using atenolol, both diltiazem and the /3-blocker were equally effective in preventing ischemia even though their effect on heart rate was markedly different. These results may reflect the importance of myocardial oxygen supply and also indicate the complexity of the interaction between supply and demand in response to various stimuli. It can be hypothesized that a common pathophysiological mechanism could lead to both an increase in demand and a reduced supply and that diltiazem could interact with this mechanism at different levels.
Exercise-induced ST depression was less frequent and, as judged by the maximum depth of ST depression, less severe during diltiazem compared with placebo exercise tests. Furthermore These issues remain to be elucidated before recommending routine treatment of silent ischemia.
